These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. Romi F; Gilhus NE; Varhaug JE; Myking A; Aarli JA Eur J Neurol; 2003 Nov; 10(6):701-6. PubMed ID: 14641516 [TBL] [Abstract][Full Text] [Related]
8. Muscle autoantibodies in subgroups of myasthenia gravis patients. Romi F; Skeie GO; Aarli JA; Gilhus NE J Neurol; 2000 May; 247(5):369-75. PubMed ID: 10896269 [TBL] [Abstract][Full Text] [Related]
9. Titin and ryanodine receptor autoantibodies in dogs with thymoma and late-onset myasthenia gravis. Shelton GD; Skeie GO; Kass PH; Aarli JA Vet Immunol Immunopathol; 2001 Jan; 78(1):97-105. PubMed ID: 11182151 [TBL] [Abstract][Full Text] [Related]
10. The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis. Chen XJ; Qiao J; Xiao BG; Lu CZ J Neurol; 2004 Aug; 251(8):1006-11. PubMed ID: 15316806 [TBL] [Abstract][Full Text] [Related]
11. [Thymectomy and muscle antibodies in myasthenia gravis]. Romi F; Gilhus NE; Aarli JA Tidsskr Nor Laegeforen; 2004 Mar; 124(5):629-31. PubMed ID: 15004605 [TBL] [Abstract][Full Text] [Related]
12. Myasthenia gravis in individuals over 40. Aarli JA; Romi F; Skeie GO; Gilhus NE Ann N Y Acad Sci; 2003 Sep; 998():424-31. PubMed ID: 14592910 [TBL] [Abstract][Full Text] [Related]
13. Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Wolfe GI; Kaminski HJ; Jaretzki A; Swan A; Newsom-Davis J Ann N Y Acad Sci; 2003 Sep; 998():473-80. PubMed ID: 14592916 [TBL] [Abstract][Full Text] [Related]
14. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Yamamoto AM; Gajdos P; Eymard B; Tranchant C; Warter JM; Gomez L; Bourquin C; Bach JF; Garchon HJ Arch Neurol; 2001 Jun; 58(6):885-90. PubMed ID: 11405802 [TBL] [Abstract][Full Text] [Related]
15. Myasthenia gravis sera containing antiryanodine receptor antibodies inhibit binding of [3H]-ryanodine to sarcoplasmic reticulum. Skeie GO; Lunde PK; Sejersted OM; Mygland A; Aarli JA; Gilhus NE Muscle Nerve; 1998 Mar; 21(3):329-35. PubMed ID: 9486861 [TBL] [Abstract][Full Text] [Related]
16. Autoimmunity to ryanodine receptor and titin in myasthenia gravis is associated with GM allotypes. Skeie GO; Pandey JP; Aarli JA; Gilhus NE Autoimmunity; 1997; 26(2):111-6. PubMed ID: 9546812 [TBL] [Abstract][Full Text] [Related]
17. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Takamori M; Motomura M; Kawaguchi N; Nemoto Y; Hattori T; Yoshikawa H; Otsuka K Neurology; 2004 May; 62(10):1894-6. PubMed ID: 15159506 [TBL] [Abstract][Full Text] [Related]
18. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. Romi F; Bø L; Skeie GO; Myking A; Aarli JA; Gilhus NE J Neuroimmunol; 2002 Jul; 128(1-2):82-9. PubMed ID: 12098514 [TBL] [Abstract][Full Text] [Related]
19. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Mygland A; Vincent A; Newsom-Davis J; Kaminski H; Zorzato F; Agius M; Gilhus NE; Aarli JA Arch Neurol; 2000 Apr; 57(4):527-31. PubMed ID: 10768628 [TBL] [Abstract][Full Text] [Related]